Compare BioNTech SE - ADR (BNTX) vs Delta Air Lines, Inc. (DAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Delta Air Lines, Inc. — how do they compare? BioNTech SE - ADR trades at $90.53 (market cap $23.31B), while Delta Air Lines, Inc. trades at $90.12 (market cap $58.67B). The key difference: Delta Air Lines, Inc. is far larger — about 2.5× BioNTech SE - ADR's market cap, and Delta Air Lines, Inc. pays a 0.87% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | DAL | |
|---|---|---|
Market Cap | $23.31B | $58.67B |
Sector | Health | Industrials |
52-Week High | $119.34 | $93.66 |
52-Week Low | $83.89 | $55.65 |
Enterprise Value | $6.60B | $73.99B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
Delta Air Lines (DAL) trades at $91.34, down 0.7% today, amid a bullish technical trend and strong fundamentals. The stock shows robust earnings beats in recent quarters, with Q3 2026 EPS expected at $2.19. Valuation metrics like a P/E of 15.15 and P/S of 0.88 suggest potential undervaluation, while cash flow trends improved to a net positive $1.08B in 2025. Recent news highlights insider sales but also strong Q2 results and industry tailwinds.
Outlook remains positive with an 81.82% analyst buy rating and consensus price target of $108.27, implying ~18% upside. Key risks include fuel cost volatility and competitive pressures, but DAL's premium travel demand and loyalty program strength support growth. Investors should weigh solid fundamentals against macroeconomic sensitivities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Delta Air Lines, Inc.
Atlanta-based Delta Air Lines is one of the world's largest airlines, with a network of over 300 destinations in more than 50 countries. Delta operates a hub-and-spoke system network, where it gathers and distributes passengers across the globe through key locations such as Atlanta, New York, Salt Lake City, Detroit, Seattle, and Minneapolis-St. Paul. Delta's sale of frequent flier miles, particularly to American Express, is a major driver of the firm's profits.
Read more on DAL →
